Skip to main content

Advertisement

Log in

Exploring the Interplay between Diabetes and Lp(a): Implications for Cardiovascular Risk

  • REVIEW
  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The objective of this manuscript is to review and describe the relationship between Lp(a) and diabetes, exploring both their association and synergy as cardiovascular risk factors, while also describing the current evidence regarding the potential connection between low levels of Lp(a) and the presence of diabetes.

Recent Findings

Epidemiological studies suggest a potential relationship between low to very low levels of Lp(a) and diabetes.

Summary

Lipoprotein(a), or Lp(a), is an intriguing lipoprotein of genetic origin, yet its biological function remains unknown. Elevated levels of Lp(a) are associated with an increased risk of cardiovascular atherosclerosis, and coexisting diabetes status confers an even higher risk. On the other hand, epidemiological and genetic studies have paradoxically suggested a potential relationship between low to very low levels of Lp(a) and diabetes. While new pharmacological strategies are being developed to reduce Lp(a) levels, the dual aspects of this lipoprotein's behavior need to be elucidated in the near future

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

Data Availability

No datasets were generated or analysed during the current study.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgözoğlu LS, Catapano AL. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925–46. https://doi.org/10.1093/eurheartj/ehac361.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Tsimikas S, Marcovina SM. Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds: JACC Review Topic of the Week. J Am Coll Cardiol. 2022;80(9):934–46. https://doi.org/10.1016/j.jacc.2022.06.019.

    Article  CAS  PubMed  Google Scholar 

  3. Di Fusco SA, Arca M, Scicchitano P, Alonzo A, Perone F, Gulizia MM, Gabrielli D, Oliva F, Imperoli G, Colivicchi F. Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target. Heart. 2022;109(1):18–25. https://doi.org/10.1136/heartjnl-2021-320708.

    Article  CAS  PubMed  Google Scholar 

  4. Thau H, Neuber S, Emmert MY, Nazari-Shafti TZ. Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease? Cardiol Ther. 2024;13(1):39–67. https://doi.org/10.1007/s40119-024-00353-w

    Article  PubMed  PubMed Central  Google Scholar 

  5. Tsamoulis D, Kosmas CE, Rallidis LS. Is inverse association between lipoprotein(a) and diabetes mellitus another paradox in cardiometabolic medicine? Expert Rev Endocrinol Metab. 2024;19(1):63–70. https://doi.org/10.1080/17446651.2023.2293108.

    Article  CAS  PubMed  Google Scholar 

  6. •• Lamina C, Ward NC. Lipoprotein (a) and diabetes mellitus. Atherosclerosis. 2022 ;349:63–71. https://doi.org/10.1016/j.atherosclerosis.2022.04.016. (This review aims to shed light on the most recent findings of epidemiological and Mendelian Randomisation studies regarding the inverse association between Lp(a) and risk of prevalent and incident diabetes.)

  7. Di Fusco SA, Maggioni AP, Scicchitano P, Zuin M, D’Elia E, Colivicchi F. Lipoprotein (a), Inflammation, and Atherosclerosis. J Clin Med. 2023;12(7):2529. https://doi.org/10.3390/jcm12072529.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Marcovina SM, Albers JJ. Lipoprotein (a) measurements for clinical application. J Lipid Res. 2016;57(4):526–37. https://doi.org/10.1194/jlr.R061648.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Kraft HG, Lingenhel A, Köchl S, et al. Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol. 1996;16(6):713–9. https://doi.org/10.1161/01.atv.16.6.713.

    Article  CAS  PubMed  Google Scholar 

  10. Erqou S, Thompson A, Di Angelantonio E, Saleheen D, Kaptoge S, Marcovina S, Danesh J. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol. 2010;55(19):2160–7. https://doi.org/10.1016/j.jacc.2009.10.080.

    Article  CAS  PubMed  Google Scholar 

  11. Lamina C. Mendelian Randomization: Principles and its usage in Lp(a) research. Atherosclerosis. 2022;349:36–41. https://doi.org/10.1016/j.atherosclerosis.2022.04.013.

    Article  CAS  PubMed  Google Scholar 

  12. Wang S, Zha L, Chen J, Du D, Liu D, Zhong M, Shang R, Sun D, Sun C, Jin E. The relationship between lipoprotein(a) and risk of cardiovascular disease: a Mendelian randomization analysis. Eur J Med Res. 2022;27(1):211. https://doi.org/10.1186/s40001-022-00825-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. •• Kronenberg F. Lipoprotein(a): from Causality to Treatment. Curr Atheroscler Rep. 2024;26(3):75–82. https://doi.org/10.1007/s11883-024-01187-6 (This paper reviews the evidence why lipoprotein(a) (Lp(a)) is a causal risk factor for cardiovascular disease and how high Lp(a) concentrations should be managed now and with an outlook to the future.)

  14. Mukamel RE, Handsaker RE, Sherman MA, Barton AR, Zheng Y, McCarroll SA, Loh PR. Protein-coding repeat polymorphisms strongly shape diverse human phenotypes. Science. 2021;373(6562):1499–505. https://doi.org/10.1126/science.abg8289.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Paige E, Masconi KL, Tsimikas S, Kronenberg F, Santer P, Weger S, Willeit J, Kiechl S, Willeit P. Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature. Cardiovasc Diabetol. 2017;16:38.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Mora S, Kamstrup PR, Rifai N, Nordestgaard BG, Buring JE, Ridker PM. Lipoprotein(a) and risk of type 2 diabetes. Clin Chem. 2010;56:1252–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Langsted A, Nordestgaard BG, Kamstrup PR. Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study. Eur Heart J. 2021;42:1147–56.

    Article  CAS  PubMed  Google Scholar 

  18. Skoumas I, Andrikou I, Grigoriou K, Dima I, Lazarou E, Vlachopoulos C, Tsioufis K. Lipoprotein(a), metabolic profile and new-onset type-2 diabetes in patients with familial combined hyperlipidemia: A 9 year follow-up study. J Clin Lipidol. 2023;17(4):512–8. https://doi.org/10.1016/j.jacl.2023.05.103.

    Article  PubMed  Google Scholar 

  19. Kamstrup PR, Nordestgaard BG. Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study. Lancet Diabetes Endocrinol. 2013;1(3):220–7. https://doi.org/10.1016/S2213-8587(13)70064-0.

    Article  CAS  PubMed  Google Scholar 

  20. Tolbus A, Mortensen MB, Nielsen SF, Kamstrup PR, Bojesen SE, Nordestgaard BG. Kringle IV Type 2, Not Low Lipoprotein(a), as a Cause of Diabetes: A Novel Genetic Approach Using SNPs Associated Selectively with Lipoprotein(a) Concentrations or with Kringle IV Type 2 Repeats. Clin Chem. 2017;63(12):1866–76. https://doi.org/10.1373/clinchem.2017.277103.

    Article  CAS  PubMed  Google Scholar 

  21. Kostner KM, Kostner GM. The 10 essential questions regarding lipoprotein(a). Curr Opin Clin Nutr Metab Care. 2024;27(2):136–43. https://doi.org/10.1097/MCO.0000000000000994.

    Article  CAS  PubMed  Google Scholar 

  22. •• Ward NC, Vickneswaran S, Watts GF. Lipoprotein (a) and diabetes mellitus: causes and consequences. Curr Opin Endocrinol Diabetes Obes. 2021 Apr 1;28(2):181–187. https://doi.org/10.1097/MED.0000000000000597. (This review provides an update on the role of lipoprotein (a) [Lp(a)] in diabetes, including its impact as a risk factor as well as its contribution to the development of cardiovascular disease.)

  23. Li M, Wang Y, Yao Q, Liang Q, Zhang Y, Wang X, Li Q, Qiang W, Yang J, Shi B, He M. Association between Lipoprotein(a) and diabetic nephropathy in patients with type 2 diabetes. Front Endocrinol (Lausanne). 2024;15(14):1337469. https://doi.org/10.3389/fendo.2023.1337469.

    Article  Google Scholar 

  24. GholamiChahkand MS, EsmaeilpourMoallem F, Qezelgachi A, Seifouri K, PesaranAfsharian A, Sheikhzadeh F, Poursalehi A, FaniSadrabadi FS, SaghabTorbati M, Ramezanzade M, Alishiri G, Ansari A, ZareDehabadi E, KarimiMatloub S, Sheikh Z, Deravi N, Mehrtabar S, Chichagi F, FaalHamedanchi N, Arzaghi M, Asadi M, AlsadatDadkhah P, Ansari A. Lipoprotein (a) as a predictor of diabetic retinopathy in patients with type 2 diabetes: A systematic review. Diab Vasc Dis Res. 2023;20(6):14791641231197114. https://doi.org/10.1177/14791641231197114.

    Article  CAS  Google Scholar 

  25. Wang P, Yuan D, Zhang C, Jia S, Song Y, Tang X, Zhao X, Gao R, Xu B, Yuan J. Association between cumulative lipoprotein(a) exposure and adverse cardiovascular outcomes in patients with prediabetes or diabetes. iscience. 2023;26(3):106117. https://doi.org/10.1016/j.isci.2023.106117.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Qi Q, Qi L. Lipoprotein(a) and cardiovascular disease in diabetic patients. Clin Lipidol. 2012;7(4):397–407. https://doi.org/10.2217/clp.12.46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Littmann K, Wodaje T, Alvarsson M, Bottai M, Eriksson M, Parini P, Brinck J. The Association of Lipoprotein(a) Plasma Levels With Prevalence of Cardiovascular Disease and Metabolic Control Status in Patients With Type 1 Diabetes. Diabetes Care. 2020;43(8):1851–8. https://doi.org/10.2337/dc19-1398.

    Article  CAS  PubMed  Google Scholar 

  28. • Thau H, Neuber S, Emmert MY, Nazari-Shafti TZ. Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease? Cardiol Ther. 2024 Mar;13(1):39–67. https://doi.org/10.1007/s40119-024-00353-w. (This comprehensive review, provide a detailed overview of RNA-based therapeutic approaches and discuss the recent advances and challenges of RNA therapeutics specifically designed to reduce Lp(a) levels and thus the risk of cardiovascular disease.)

  29. Schmidt AM. Diabetes Mellitus and Cardiovascular Disease. Arterioscler Thromb Vasc Biol. 2019;39(4):558–68. https://doi.org/10.1161/ATVBAHA.119.310961.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Contributions

P.C., M.A.,A.L.C.,S.G. and N.F.R. (all the authors) have contributed to the manuscript equally (text and figure) and have reviewed the manuscript as well

Corresponding author

Correspondence to Corral Pablo.

Ethics declarations

Competing interests

The authors declare no competing interests.

Human And Animal Rights And Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pablo, C., Matías, A., Lavalle Cobo, A. et al. Exploring the Interplay between Diabetes and Lp(a): Implications for Cardiovascular Risk. Curr Diab Rep 24, 167–172 (2024). https://doi.org/10.1007/s11892-024-01543-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-024-01543-5

Keywords

Navigation